Clinical factors associated with prognosis
| Factor . | Prognostic impact . | PET scan . | Deauville score . | Reference . |
|---|---|---|---|---|
| Early disease progression after first-line chemoimmunotherapy (within 2 y) with R-CHOP, R-CVP, R-fludarabine | OS of 34% to 50% in early-relapse group; OS of 90% in reference group without early relapse | 14 | ||
| Early disease progression after first-line chemoimmunotherapy (within 1 y) | SMR, 3.90; 95% CI, 2.89-5.25; P < .001 | 31 | ||
| PET response | 4 y PFS, 63%; OS, 95% | Positive | 4 or 5 | 27 |
| Factor . | Prognostic impact . | PET scan . | Deauville score . | Reference . |
|---|---|---|---|---|
| Early disease progression after first-line chemoimmunotherapy (within 2 y) with R-CHOP, R-CVP, R-fludarabine | OS of 34% to 50% in early-relapse group; OS of 90% in reference group without early relapse | 14 | ||
| Early disease progression after first-line chemoimmunotherapy (within 1 y) | SMR, 3.90; 95% CI, 2.89-5.25; P < .001 | 31 | ||
| PET response | 4 y PFS, 63%; OS, 95% | Positive | 4 or 5 | 27 |
SMR, standard mortality ratio.